Chemomab Therapeutics Ltd - ADR (O:CMMB)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

May 17, 2024 07:00 am ET

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced upcoming scientific presentations at the Gordon...

May 09, 2024 07:00 am ET

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Chemomab Therapeutics Ltd. (Nasdaq:CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first...

May 08, 2024 07:00 am ET

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

May 02, 2024 07:00 am ET

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

Apr 24, 2024 07:00 am ET

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will report its first quarter 2024...

Apr 18, 2024 07:00 am ET

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced the publication of a new study that...

Apr 02, 2024 07:00 am ET

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

Mar 25, 2024 07:06 am ET

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Feb 20, 2024 06:00 am ET

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

—CM-101 Phase 2 Trial for the Treatment of Primary Sclerosing Cholangitis (PSC) Has Completed Patient Enrollment with Topline Data Expected Midyear 2024—

Feb 14, 2024 06:00 am ET

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

TEL AVIV, Israel, Feb. 14, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its fourth quarter and full year 2023 financial results and providing a business update on March 7, 2024, at 7:00 am Eastern Time.

Feb 05, 2024 06:00 am ET

Chemomab Therapeutics to Participate in Upcoming Investor Conferences

TEL AVIV, Israel, Feb. 5, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr. Adi Mor and other members of its senior management team will participate in two upcoming investor conferences. Dr. Mor will deliver a corporate presentation and participate in one-on-one investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, February 13-14, 2024 (virtual), a

Jan 30, 2024 06:00 am ET

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

—Proteomic Analysis of Human Samples Highlights the Unique Role of CCL24 in Activating Key PSC-related Disease Mechanisms Involving Immune Cell Trafficking and HSC Activation, Further Confirming the Potential of Chemomab's CCL24-Neutralizing Antibody CM-101 as a Promising Therapy for PSC—

Jan 03, 2024 06:00 am ET

Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024

—Expected Topline Data Readout Accelerated to Midyear 2024 Following Early Completion of Patient Enrollment in Phase 2 Primary Sclerosing Cholangitis (PSC) SPRING Trial—

Nov 16, 2023 06:00 am ET

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

--Systemic Sclerosis (SSc) Patient Data Shows High Serum CCL24 Levels Associated with More Severe Manifestations of Disease, Including Pulmonary Arterial Hypertension --

Nov 15, 2023 06:00 am ET

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis

—CM-101's Unique Dual Anti-Fibrotic and Anti-Inflammatory Activity Has Disease Modifying Potential in this Poorly Treated Condition—

Nov 13, 2023 07:00 am ET

Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with K

—New Proteomic Analyses of Phase 2a Liver Fibrosis Clinical Data Show Consistent and Significant Improvements in Liver-related Pathology Pathways After Treatment with CM-101—

Nov 09, 2023 07:00 am ET

Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

—Continued Strong Progress in Advancing CM-101 Phase 2 PSC Trial Towards Completion of Enrollment--On Track for Topline Readout in Second Half of 2024—

Nov 06, 2023 03:15 pm ET

Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

--Chemomab's ADSs Will Continue to Trade on the Nasdaq Capital Market--

Oct 30, 2023 07:00 am ET

Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update

TEL AVIV, Israel, Oct. 30, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will release its third quarter 2023 financial results and a business update on November 9, 2023 at 8:00 am Eastern Time.

Oct 26, 2023 07:00 am ET

Chemomab Therapeutics to Present at Upcoming Scientific Conferences

TEL AVIV, Israel, Oct. 26, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will present at major U.S. scientific conferences in November, including an oral presentation on primary sclerosing cholangitis and a poster at the AASLD The Liver Meeting® 2023, as well as a poster presentation on the role of Chemomab's CCL24 target in manifestations of systemic sclerosis at the American

Sep 28, 2023 07:00 am ET

Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference

--CM-101's Unique Dual Anti-Fibrotic and Anti-Inflammatory Activity Supports Its Disease Modifying Potential in Primary Sclerosing Cholangitis (PSC)---

Jun 28, 2023 07:00 am ET

Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis

--Includes Extensive Data Showing that CM-101, Chemomab's CCL24-Neutralizing Antibody, Interrupts the Fibro-Inflammatory Processes that Lead to PSC--

Jun 26, 2023 07:00 am ET

Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023

--New Proteomics Data Further Confirms the Relationship between CM-101's CCL24 Target and Primary Sclerosing Cholangitis (PSC) Disease Pathways--

Jun 21, 2023 07:00 am ET

Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023

─Treatment with CM-101 Improves Additional Biomarkers of Fibrosis and Inflammation, `Reinforcing and Extending Initial Study Results─

Jun 05, 2023 07:00 am ET

Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update

─Adi Mor, PhD, Co-founder, Board Director and Chief Scientific Officer, Reappointed to CEO Role─

Jun 02, 2023 09:00 am ET

Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis

──New Patient Data Further Implicates CCL24 in Fibrotic Disease Pathology and Prognosis and Supports Rationale for the Role of Chemomab's CCL24-Neutralizing Antibody CM-101in Systemic Sclerosis and Other Fibro-inflammatory Diseases──

May 24, 2023 07:00 am ET

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

TEL AVIV, Israel, May 24, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced upcoming CM-101 data presentations at major European scientific conferences in June 2023, including EULAR23, the European Congress of Rheumatology, and EASL 2023, the Annual Congress of the European Association for the Study of the Liver. Further details of the presented data will be forthcoming.

May 11, 2023 06:00 am ET

Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update

─Reported Top-line Results from CM-101 Phase 2 Liver Fibrosis Trial in NASH Patients Demonstrating Safety and Positive Activity Across Multiple Fibrotic and Inflammatory Biomarkers─

Apr 26, 2023 07:00 am ET

Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference

TEL AVIV, Israel, April 26, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company will participate in the Aegis Virtual Conference being held May 2–May 4, 2023. Chemomab management will present a corporate overview on Wednesday, May 3, 2023.

Apr 19, 2023 07:00 am ET

Chemomab Therapeutics to Present at Upcoming Scientific Conferences

TEL AVIV, Israel, April 19, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company will participate in a number of scientific conferences in April and May.

Apr 12, 2023 07:00 am ET

Chemomab Therapeutics to Discuss First Quarter 2023 Financial Results and Provide a Corporate Update

This Webcast and Call Replaces and Supplements the Chemomab Corporate Update Originally Scheduled for April 17, 2023

Mar 29, 2023 08:30 am ET

Chemomab Therapeutics to Provide a Corporate Update on April 17, 2023

TEL AVIV, Israel, March 29, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will provide a Corporate Update on Monday, April 17, 2023, at 8:00 am Eastern Time. This event replaces the webcast and call originally scheduled for March 31, 2023.

Mar 17, 2023 07:00 am ET

Chemomab Therapeutics to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide a Business Update

TEL AVIV, Israel, March 17, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will discuss its fourth quarter and full-year 2022 financial results and provide a business update on Friday, March 31, 2023, at 8:00 am Eastern Time.

Feb 21, 2023 06:00 am ET

Chemomab Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with Systemic Sclerosis

—ABATE Phase 2 Trial Aims to Further Assess Safety and Establish Biological and Clinical Proof-of-Concept for CM-101 as a Potential Treatment for Patients with Systemic Sclerosis—

Jan 03, 2023 07:51 am ET

Thinking about buying stock in Sorrento Therapeutics, Jasper Therapeutics, Chemomab Therapeutics, ACM Research, or Evaxion Biotech?

NEW YORK, Jan. 3, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRNE, JSPR, CMMB, ACMR, and EVAX.

Jan 03, 2023 06:00 am ET

Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients

—CM-101 Met Primary Endpoint of Safety and Tolerability and Showed Positive Activity Across Multiple Liver Fibrosis Biomarkers and Physiologic Assessments—

Dec 21, 2022 06:00 am ET

Chemomab Reports Independent Drug Monitoring Committee Safety Review of CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis

—Clean Safety Review Supports Addition of Higher Dose Cohort into the Trial—

Nov 30, 2022 06:00 am ET

Chemomab Announces Appointment of Mitchell L. Jones, MD, PhD as Vice President of Corporate Development & Strategy

TEL AVIV, Israel, Nov. 30, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the appointment of Mitchell L. Jones, MD, PhD, as Vice President of Corporate Development & Strategy. Dr. Jones brings Chemomab more than 15 years of leadership experience in biopharmaceutical research, clinical development, corporate strategy and entrepreneurship, organizational development and team-build

Nov 11, 2022 05:00 am ET

Chemomab Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

─Chemomab to Host Conference Call for Investors Today, November 11 at 8:00 am ET─

Nov 09, 2022 07:00 am ET

Chemomab Presents Clinical Data from Investigator-Initiated Study Showing CM-101 Reduced Inflammatory and Fibrogenesis-Related Biomarkers in Patients with Severe Lung Injury Derived from Covid-19

─New Findings Demonstrate CM-101's Anti-Inflammatory and Anti-Fibrotic Effects Are Highly Relevant to Inflammatory Lung Diseases─

Nov 01, 2022 07:00 am ET

Chemomab Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Business Update

TEL AVIV, Israel, Nov. 1, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its third quarter 2022 financial results and provide a business update on Friday, November 11, 2022 at 8:00 am Eastern Time.

Oct 28, 2022 07:00 am ET

Chemomab Therapeutics to Present at Upcoming Scientific Conferences

TEL AVIV, Israel, Oct. 28, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company will participate in several scientific conferences in November.

Aug 12, 2022 06:00 am ET

Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities

─Appoints Ilan Vaknin, PhD, as Vice President of Research & Development and Christina Crater, MD, as Vice President of Clinical Development─

Aug 12, 2022 06:00 am ET

Chemomab Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

─Chemomab to Host Webcast and Conference Call for Investors Today, August 12 at 8:00 am ET─

Aug 01, 2022 07:00 am ET

Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update

TEL AVIV, Israel, Aug. 1, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its second quarter 2022 financial results and provide a business update on Friday, August 12, 2022 at 8:00 am Eastern Time.

Jun 27, 2022 08:00 am ET

Chemomab Presents Data Further Supporting the Mechanism of Action and Potential Efficacy of CM-101 in Primary Sclerosing Cholangitis

—Data Presented at 2022 EASL International Liver ConferenceTM and First International Extracellular Matrix Pharmacology Congress—

Jun 21, 2022 07:00 am ET

Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors

—Ms. Quigley's Broad Biotechnology Industry Experience Encompasses Leadership Positions in Executive Management, Operations and Legal Affairs—

Jun 09, 2022 09:00 am ET

Chemomab Therapeutics to Present at June Investor and Scientific Conferences

TEL AVIV, Israel, June 9, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that the company will participate in a number of investor and scientific conferences in June 2022.

Jun 02, 2022 07:00 am ET

Data Supporting Role of Chemomab's Novel Therapeutic Target CCL24 in Systemic Sclerosis Presented at EULAR 2022

—Poster Presentation of Reverse Translational Study Data Using Patient Samples Supports Role of CCL24 as a Therapeutic Target for Systemic Sclerosis—

May 18, 2022 07:00 am ET

Chemomab Therapeutics to Participate in H.C. Wainwright Global Investment Conference

TEL AVIV, Israel, May 18, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that management will participate in the virtual portion of the H.C. Wainwright Global Investment Conference, which will take place May 23-26, 2022.

May 12, 2022 06:00 am ET

Chemomab Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update

-- Company to Host Conference Call for Investors Today, May 12 at 8:00 am ET --

May 04, 2022 07:00 am ET

Chemomab Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update

TEL AVIV, Israel, May 4, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its first quarter 2022 financial results and provide a business update on Thursday, May 12, 2022. The company will host a conference call at 8:00 am Eastern Time, which will be webcast at the link below and on the company's investor relations website.

Mar 23, 2022 07:00 am ET

Chemomab Therapeutics to Participate in Cantor Fitzgerald Rare Orphan Disease Summit

TEL AVIV, Israel, March 23, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that management will participate in a panel discussion at the virtual Cantor Fitzgerald Rare Orphan Disease Summit on March 29, 2022.

Mar 14, 2022 08:00 am ET

Chemomab Reports on Two Scientific Presentations that Support the Potential Therapeutic Utility of CM-101 in Systemic Sclerosis

—Translational Study Data Presented at 7th Systemic Sclerosis World Congress Confirms CCL24 is Elevated in Diffuse Cutaneous Systemic Sclerosis Patients; High CCL24 Serum Levels in Patients were Correlated with Greater Disease Activity and Worse Prognosis—

Mar 09, 2022 05:00 am ET

Chemomab Therapeutics Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update

TEL AVIV, Israel, March 9, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced financial and operating results for the fourth quarter and year ended December 31, 2021, and provided a corporate update.

Mar 02, 2022 07:00 am ET

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business Update

TEL AVIV, Israel, March 2, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its fourth quarter and full year 2021 financial results and provide a business update on Wednesday, March 9, 2022. The company will host a conference call and webcast at 8:00 a.m. Eastern Time on the same day, which will be broadcast live at the link below and on the company's investo

Feb 10, 2022 07:00 am ET

Chemomab Therapeutics to Present at Aegis Virtual Conference

TEL AVIV, Israel, Feb. 10, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that it will present a company overview at the Aegis Capital Corp. Virtual Conference on February 24, 2022, at 9:00 am ET.

Jan 04, 2022 06:00 am ET

Chemomab Therapeutics Names Jack Lawler Vice President of Global Clinical Development Operations

TEL AVIV, Israel, Jan. 4, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today named Jack Lawler Vice President of Global Clinical Development Operations. Mr. Lawler, who is based in the U.S., brings more than 22 years of clinical drug development experience, including contributing to the development of eight approved pharmaceutical products across a variety of therapeutic indications.

Dec 20, 2021 07:00 am ET

Chemomab to Participate in LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference

TEL AVIV, Israel, Dec. 20, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that senior management will participate in the LifeSci Partners 11th Annual Corporate Access Event, which will be held virtually from January 5-7, 2022, and the H.C. Wainwright BioConnect Conference, which will be held virtually from January 10-13, 2022.

Dec 16, 2021 03:05 pm ET

Chemomab Therapeutics Announces Expected Appointment of Dale R. Pfost as Chairman of the Board

TEL AVIV, Israel, Dec. 16, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab) a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that, as planned and announced earlier this year, CEO Dale R. Pfost, PhD will assume the additional role of Chairman, subject to the approval of Chemomab's shareholders, as is required under Israeli law. A shareholder vote is expected to be held in or around February 2022. Stephen Squinto, PhD, will be leaving

Dec 03, 2021 07:00 am ET

Chemomab Therapeutics Names David M. Weiner, MD as Interim Chief Medical Officer

TEL AVIV, Israel, Dec. 3, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (NASDAQ: CMMB), (Chemomab) a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that David M. Weiner, MD has been named Interim Chief Medical Officer, effective immediately. This position will be in a part-time capacity. Dr. Weiner is replacing Dr. Arnon Aharon, who has resigned. Dr. Aharon intends to continue at Chemomab for the next 60 days and as a senior medical advisor thereafter to ensure a

Nov 12, 2021 06:00 am ET

Chemomab Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update

TEL AVIV, Israel, Nov. 12, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced financial and operating results for the third quarter ended September 30, 2021, and provided a corporate update.

Nov 10, 2021 06:00 am ET

Chemomab Announces Poster Presentation at AASLD's The Liver Meeting® 2021

TEL AVIV, Israel, Nov. 10, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced a poster presentation at The Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), being held virtually November 12-15, 2021.

Nov 09, 2021 06:00 am ET

Chemomab to Present at Stifel 2021 Virtual Healthcare Conference

TEL AVIV, Israel, Nov. 9, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced it will host a live presentation and participate in 1-on-1 investor meetings at Stifel's 2021 Virtual Healthcare Conference.

Nov 08, 2021 06:00 am ET

Chemomab Therapeutics Names Donald R. Marvin Chief Financial Officer, Executive Vice President and Chief Operating Officer

TEL AVIV, Israel, Nov. 8, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab) a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that Donald R. Marvin has been named Chief Financial Officer, Executive Vice President and Chief Operating Officer. Mr. Marvin is a seasoned biotechnology executive with over 35 years of experience at growth enterprises in corporate finance and fundraising, strategy, corporate development, mergers and acquisitions, an

Oct 26, 2021 08:53 am ET

Chemomab Therapeutics Hosting Key Opinion Leader Webinar on Systemic Sclerosis

TEL AVIV, Israel, Oct. 26, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) ("Chemomab"), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that it will host a key opinion leader (KOL) live webinar featuring systemic sclerosis (SSc) expert Dr. Dinesh Khanna on Wednesday, November 3, 2021, at 10:00 am Eastern Time.

Sep 27, 2021 07:00 am ET

Chemomab Therapeutics Announces Collaboration with Leeds University to Further Elucidate the Role of CCL24 in Vascular Damage Associated with Systemic Sclerosis

TEL AVIV, Israel, Sept. 27, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) ("Chemomab"), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced a research collaboration with Leeds University to further study the role of CCL24 in the vascular damage associated with systemic sclerosis (SSc), a rare rheumatic disease with high morbidity and mortality. The collaboration will be led by Francesco Del Galdo, MD, PhD, Professor of Experimental Medicine at the Uni

Sep 02, 2021 07:00 am ET

Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer

TEL AVIV, Israel, Sept. 2, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for inflammatory and fibrotic diseases with high unmet need, today announced it has appointed Dale R. Pfost, PhD, as Chief Executive Officer (CEO). Dr. Adi Mor, Company co-founder and current CEO, will continue in her role as Chief Scientific Officer (CSO) and remain as a member of the Board of Directors. The addition of Dr. Pfost, who brings more than 30 years of diverse experience as a life science se

Sep 01, 2021 07:18 am ET

Chemomab to Participate in Upcoming September Investor Conferences

TEL AVIV, Israel, Sept. 1, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced that the Company will participate in the following upcoming investor conferences in September:

Aug 13, 2021 08:00 am ET

Chemomab Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update

TEL AVIV, Israel, Aug. 13, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced financial and operating results for the second quarter ended June 30, 2021 and provided a business update.

Jun 23, 2021 08:30 am ET

Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III

TEL AVIV, Israel and SEATTLE, June 23, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, and AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced an expanded partnership to manufacture CM-101, a Phase II investigational drug targeting Primary Sclerosing Cholangitis, Systemic Sclerosis, and Liver Fibrosis MoA (NASH). Under terms of the agreement, the compa

Jun 23, 2021 08:30 am ET

Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III

Chemomab Therapeutics, Ltd. (NASDAQ: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, and AGC Biologics, a leading global...

Jun 11, 2021 08:30 am ET

Thinking about buying stock in Novan, Chemomab Therapeutics, Precigen, ChemoCentryx, or Senseonics?

NEW YORK, June 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NOVN, CMMB, PGEN, CCXI, and SENS.

Jun 10, 2021 07:00 am ET

Chemomab Announces Poster Presentation at the International Liver Congress 2021 (EASL)

TEL AVIV, Israel, June 10, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced a poster presentation at the International Liver Congress 2021 (EASL), which is being held virtually on June 23-26, 2021.

Ad blocking detected

Chemomab Therapeutics Ltd - ADR (O:CMMB)

Business Focus: Bio Therapeutic Drugs